Hong Kong SAR
Transforming Healthcare & Longevity Through Regenerative Medicine At Celljevity, we are shaping the future of healthcare. As Co-Founder & CEO, I lead a pioneering regenerative medicine company focused on developing autologous rejuvenated stem-cell therapies designed to repair and restore the body at a cellular level. Celljevity’s proprietary fibroblast rejuvenation technology represents a significant advance in regenerative science. By rejuvenating a patient’s own cells, without genetic modification, we aim to safely address the underlying biological drivers of degenerative diseases, autoimmune disorders, and age-related conditions, with the broader ambition of extending both healthspan and lifespan. Our platform enables us to: - Rejuvenate autologous cells to a near-newborn functional state, avoiding the risks associated with genetic alteration. - Support telomere lengthening and epigenetic reprogramming, targeting fundamental mechanisms of aging and reversing one's biological clock by 10-15 years. - Deliver clinically meaningful outcomes in conditions such as ALS, Parkinson’s, Alzheimer’s disease, Osteoarthritis, and Autoimmune disorders, with over 1,000 patients treated to date. Driven by a mission to provide safe, non-toxic, and transformative therapies, Celljevity is scaling globally and preparing for a NASDAQ or Hong Kong market listing in 2026, supporting broader access to next-generation regenerative treatments. I am deeply committed to integrating cutting-edge biomedical science with holistic and preventive principles, bridging advanced technology with insights from plant-based and systems medicine. At Celljevity, we are not simply treating symptoms, we are addressing root causes and redefining how healthcare and longevity medicine are delivered. Follow me to stay informed on Celljevity’s journey and the evolving future of regenerative medicine and human longevity. Rewrite with AI